ArticleNature immunology2012
A new therapeutic strategy for malaria: targeting T cell exhaustion.
Article in Nature immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04661579 (A Phase 2b Randomized, Open-label, Controlled, Single Center Study in Plasmodium Falciparum-infected and Uninfected Adults Age 18-55 Years Old in Kenya to Evaluate the Efficacy of the Delayed, Fractional Dose RTS,S/AS01E Malaria Vaccine in Subjects Treated With Artemisinin Combination Therapy Plus Primaquine), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2b Randomized, Open-label, Controlled, Single Center Study in Plasmodium Falciparum-infected and Uninfected Adults Age 18-55 Years Old in Kenya to Evaluate the Efficacy of the Delayed, Fractional Dose RTS,S/AS01E Malaria Vaccine in Subjects Treated With Artemisinin Combination Therapy Plus Primaquine
Who cites it
13 citing papers in PubMed.
- Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic Plasmodium falciparum-Exposed, Drug-Treated Kenyan Adults.The Journal of infectious diseases · 2025Trial
- Chronic malaria exposure is associated with inhibitory markers on T cells that correlate with atypical memory and marginal zone-like B cells.Clinical and experimental immunology · 2024Article
- Advances in understanding the role of immune checkpoint LAG-3 in tumor immunity: a comprehensive review.Frontiers in oncology · 2024Review
- Exhausted CD4Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Article
- Control of NK Cell Activation by Immune Checkpoint Molecules.International journal of molecular sciences · 2017Review
- Parasites and immunotherapy: with or against?Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2016Article
- Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.Bladder cancer (Amsterdam, Netherlands) · 2016Article
- Diacylglycerol Kinases (DGKs): Novel Targets for Improving T Cell Activity in Cancer.Frontiers in cell and developmental biology · 2016Review
- Combination cancer immunotherapy and new immunomodulatory targets.Nature reviews. Drug discovery · 2015Review
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.Clinical therapeutics · 2015Review
- Ribonucleic acid (RNA) biosynthesis in human cancer.Cancer cell international · 2015Article
- Cross-reactive immune responses as primary drivers of malaria chronicity.Infection and immunity · 2014Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.